Photo generated from www.thelancet.com
Apr 8, 2024, 15:49
Paolo Tarantino: The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, recently shared on X:
“The TRAIN3 trial of MRI-guided TCHP (3, 6 or 9 cycles) is out in The Lancet Oncology. MRI identified patients with HR-/HER2+ breast cancer having pCR after only 3 cycles of TCHP. May it be MRI, PET, GEP, or ctDNA, the future of treatment for HER2+ eBC will be biomarker driven.”
Read further.
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 14:05
Nov 13, 2024, 12:13
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10